Skip to main content
Clinical Trials/NCT05912972
NCT05912972
Recruiting
N/A

Development and Management of Registry in Patients With Gynecologic Cancer in Korea

Asan Medical Center1 site in 1 country13,500 target enrollmentOctober 21, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cervical Cancer
Sponsor
Asan Medical Center
Enrollment
13500
Locations
1
Primary Endpoint
Overall survival
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer patients. Ultimately, the final goal is to contribute to the development of safe surgical methods and treatment for gynecologic cancer to improve survival rates.

Detailed Description

Cervical cancer, endometrial cancer, and ovarian cancer represent gynecologic cancers. There are many open issues that need to be addressed, specifically the surgical method, disease recurrence and survival outcome in the so called "real world" setting. The aim of this observational study is to collect both retrospective and prospective medical information of gynecologic cancer patients.

Registry
clinicaltrials.gov
Start Date
October 21, 2022
End Date
October 21, 2027
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jeong-Yeol Park, MD, PhD

Professor

Asan Medical Center

Eligibility Criteria

Inclusion Criteria

  • Female patients 18 years or older
  • Written informed consent (prospective cohort)
  • Confirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer

Exclusion Criteria

  • Unconfirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer

Outcomes

Primary Outcomes

Overall survival

Time Frame: 5 years

Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to baseline characteristics, surgical methods, and treatment

Secondary Outcomes

  • Progression-free survival(5 years)

Study Sites (1)

Loading locations...

Similar Trials